Article

Understanding the development of human bladder cancer by using a whole-organ genomic mapping strategy.

Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Laboratory Investigation (Impact Factor: 3.83). 08/2008; 88(7):694-721. DOI: 10.1038/labinvest.2008.27
Source: PubMed

ABSTRACT The search for the genomic sequences involved in human cancers can be greatly facilitated by maps of genomic imbalances identifying the involved chromosomal regions, particularly those that participate in the development of occult preneoplastic conditions that progress to clinically aggressive invasive cancer. The integration of such regions with human genome sequence variation may provide valuable clues about their overall structure and gene content. By extension, such knowledge may help us understand the underlying genetic components involved in the initiation and progression of these cancers. We describe the development of a genome-wide map of human bladder cancer that tracks its progression from in situ precursor conditions to invasive disease. Testing for allelic losses using a genome-wide panel of 787 microsatellite markers was performed on multiple DNA samples, extracted from the entire mucosal surface of the bladder and corresponding to normal urothelium, in situ preneoplastic lesions, and invasive carcinoma. Using this approach, we matched the clonal allelic losses in distinct chromosomal regions to specific phases of bladder neoplasia and produced a detailed genetic map of bladder cancer development. These analyses revealed three major waves of genetic changes associated with growth advantages of successive clones and reflecting a stepwise conversion of normal urothelial cells into cancer cells. The genetic changes map to six regions at 3q22-q24, 5q22-q31, 9q21-q22, 10q26, 13q14, and 17p13, which may represent critical hits driving the development of bladder cancer. Finally, we performed high-resolution mapping using single nucleotide polymorphism markers within one region on chromosome 13q14, containing the model tumor suppressor gene RB1, and defined a minimal deleted region associated with clonal expansion of in situ neoplasia. These analyses provided new insights on the involvement of several non-coding sequences mapping to the region and identified novel target genes, termed forerunner (FR) genes, involved in early phases of cancer development.

Download full-text

Full-text

Available from: Ronald Alan Harris, Jun 27, 2015
0 Followers
 · 
171 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Bladder cancer (or urothelial cell carcinoma [UCC]) is characterized by field disease (malignant alterations in surrounding mucosa) and frequent recurrences. Whole-genome, exome, and transcriptome sequencing of 38 tumors, including four metachronous tumor pairs and 20 superficial tumors, identified an APOBEC mutational signature in one-third. This was biased toward the sense strand, correlated with mean expression level, and clustered near breakpoints. A > G mutations were up to eight times more frequent on the sense strand (p < 0.002) in [ACG]AT contexts. The patient-specific APOBEC signature was negatively correlated to repair-gene expression and was not related to clinicopathological parameters. Mutations in gene families and single genes were related to tumor stage, and expression of chromatin modifiers correlated with survival. Evolutionary and subclonal analyses of early/late tumor pairs showed a unitary origin, and discrete tumor clones contained mutated cancer genes. The ancestral clones contained Pik3ca/Kdm6a mutations and may reflect the field-disease mutations shared among later tumors.
    Cell Reports 05/2014; 7(5). DOI:10.1016/j.celrep.2014.04.038 · 7.21 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Bladder cancer, arising from the transitional cells of the mucosal urothelium, may present as a noninvasive, papillary tumor protruding from the mucosal surface, or as a solid, nonpapillary tumor that invades the bladder wall and has a high propensity for metastasis. The nonpapillary tumors originate from in situ dysplasia. The most common environmental risk for bladder cancer is active smoking; occupational exposure to arsenic or other carcinogens is also a risk factor. A possible familial component to bladder cancer has been described. Conventional models of carcinogenesis suppose the existence of successive mutation events within a specific cell clone, enabling its eventual escape from regulation of cell division and maintenance of genomic integrity. Important new information has emerged from whole-organ mapping of the mucosal genome in bladders resected for invasive cancer (Majewski et al, Lab Invest; published online 5 May 2008). Mapping of genetic hits across the entire mucosa demonstrates genetic alterations in six chromosomal regions, not only in mucosal regions of evident dysplasia, but also in morphologically normal mucosa. These clonally expanded regions cover vast expanses of the bladder surface, as a 'first wave' of pre-neoplasia. Target genes in these regions are termed 'forerunner genes' (FR genes), based on the concept that these genes enable the initial clonal expansion of in situ urothelial neoplasia. Extensive further analysis of human populations with urothelial cancer implicates genetic polymorphisms in one of these genes, P2RY5, as being present in a familial cluster of cancers of multiple organs, and as imparting risk for development of bladder cancer in active smokers. P2RY5 is a gene encoded within intron 17 of RB1, a prototypic tumor suppressor gene whose expression is lost at a later stage of bladder carcinogenesis. Alterations of the FR gene status provide a novel opportunity to screen individuals at risk for the earliest stage of bladder pre-neoplasia and represent attractive targets for therapeutic and chemopreventive interventions. These findings support the hypothesis that bladder carcinogenesis is initiated by clonal expansion of genetically altered but histologically normal cells that cover broad expanses of the mucosa. Effort must now be given to identifying the biological function of these novel FR genes.
    Laboratory Investigation 08/2008; 88(7):686-93. DOI:10.1038/labinvest.2008.48 · 3.83 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The close of a 5-year editorship gives opportunity to reflect on the highs and the lows of an editorship. The goal of such reflection is to assist both authors and reviewers in interacting with a biomedical journal, and to foster interest among individuals contemplating an editorship. Among the highs was the privilege of publishing high-quality original scientific work within the scope of the journal; in this instance mechanistic studies of disease. Although review articles and editorials have their reward, it is the publication of original peer-reviewed work that constitutes the true basis for advancing biomedical science. This is the heart of journal publication. Second, the editorial interaction with submitting authors in bringing their work to publication is itself highly rewarding, and can lead to longer-term collegial working relationships between editors and authors. The anonymous expert reviewers also play a key role in bringing outstanding scientific work to successful publication. Collectively, authors, editors, and reviewers constitute an important 'community of science'. Third, working together as an editorial team, especially through the weekly 'journal clubs' that a regular editorial meeting affords, is commended as a key reward of any editorial group taking on journal management. The lows included sifting through submitted manuscripts in which the rigor of science was not satisfactory, and encountering specific instances of compromised scientific integrity--fortunately rare. In both instances, the editorial commitment is to publish high-quality original science; a necessary corollary is identifying those submissions, through rigorous but fair review, which do not meet journal standards. In the end, editorship is a highly rewarding experience, and very much conducive to sustaining the wonder of science that drew us to this profession.
    Laboratory Investigation 01/2009; 88(12):1258-63. DOI:10.1038/labinvest.2008.113 · 3.83 Impact Factor